Lonza Group Aktie

Lonza Group AAQS 2024

Lonza Group AAQS

7

Ticker

LONN.SW

ISIN

CH0013841017

WKN

928619

Lonza Group har en aktuel AAQS på 7. En høj AAQS kan betragtes som et positivt tegn på, at virksomheden udvikler sig succesfuldt. Investorerne kan forvente, at virksomheden er på rette spor mod at skabe overskud. På den anden side er det vigtigt at betragte AAQS for aktien Lonza Group i forhold til de opnåede overskud og sammenligne med andre virksomheder i samme branche. En høj AAQS er ikke en absolut garanti for en positiv fremtid. Det er kun på den måde, man kan få et komplet billede af virksomhedens præstationer. For bedre at kunne vurdere virksomhedens udvikling er det vigtigt at betragte AAQS i sammenligning med andre virksomheder i samme branche. Generelt bør investorer altid betragte en virksomheds AAQS i sammenhæng med andre nøgletal som overskud, EBIT, cash flow og andre for at træffe en velbaseret investeringsbeslutning.

Lonza Group Aktienanalyse

Hvad gør Lonza Group?

The Lonza Group AG is a global company based in Basel, Switzerland. It was founded in 1897 and has since had a long history of operational excellence and innovation. Lonza is a leading provider of customized chemical and biotechnological solutions and services for customers in the health, agrochemical, life science, and other sectors. Lonza's business model is based on providing customized, customer-oriented solutions for complex chemical and biological challenges. The company focuses on three main divisions: Pharma & Biotech, Consumer Health, and Specialty Ingredients. Within these divisions, Lonza offers a variety of products, services, and solutions tailored to meet the specific needs of its customers. In the Pharma & Biotech division, Lonza offers a wide range of products and services for the pharmaceutical and biotechnology industries. The company is a global leader in active ingredients for the pharmaceutical industry and also provides custom process development and manufacturing services for biopharmaceuticals and small molecules. In the Consumer Health division, Lonza develops and produces a variety of dietary supplements, cosmetic products, and household products for its customers. The company is a recognized expert in the formulation and production of high-quality dietary supplements and has also established a strong position in the production of natural cosmetic products in recent years. Lonza's Specialty Ingredients division offers a wide range of chemical and biotechnological products and services for the life science and specialty chemical industries. This includes products and services such as microbial control, material protection, custom development services, and others. Lonza is a leading manufacturer and supplier of dietary supplements, pharmaceutical active ingredients, agrochemicals, cosmetic ingredients, and other chemical and biotechnological products. The company has extensive expertise in process development and optimization, as well as in the manufacturing of products for various industries. One of Lonza's key products is the active ingredient Mipomersen, which is used in the treatment of familial hypercholesterolemia. Lonza is also a major provider of dietary supplements, particularly vitamins, minerals, omega-3 fatty acids, and other nutrients that can promote and support human health. Another important product of Lonza is the biosimilar component recombinant human insulin, which is used in the treatment of diabetes. Overall, Lonza is an innovative and leading company in the field of chemistry and biotechnology. With a strong focus on customer-oriented solutions and a broad portfolio of products and services, the company is well positioned to meet the growing demand for chemical and biological solutions in various industries. Lonza Group ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Ofte stillede spørgsmål om Lonza Group aktien

Aktiespareplaner tilbyder en attraktiv mulighed for investorer at opbygge formue på lang sigt. En af de største fordele er den såkaldte cost-average-effekt: Ved regelmæssigt at investere et fast beløb i aktier eller aktiefonde, køber man automatisk flere andele, når priserne er lave, og færre, når de er høje. Dette kan føre til en mere fordelagtig gennemsnitspris per andel over tid. Desuden giver aktiespareplaner også småinvestorer adgang til dyre aktier, da de kan deltage med små beløb. Den regelmæssige investering fremmer også en disciplineret investeringsstrategi og hjælper med at undgå følelsesladede beslutninger, som impulsiv køb eller salg. Derudover drager investorer fordel af den potentielle værdistigning af aktierne samt af udbytteudlodninger, der kan geninvesteres, hvilket forstærker renters rente effekten og dermed væksten af det investerede kapital.

Andere Kennzahlen von Lonza Group

Vores aktieanalyse af Lonza Group Omsætning-aktien indeholder vigtige finansielle nøgletal som omsætning, profit, P/E-ratioen, P/S-ratioen, EBIT samt informationer om udbytte. Desuden ser vi på aspekter som aktier, markedskapitalisering, gæld, egenkapital og forpligtelser hos Lonza Group Omsætning. Hvis du søger mere detaljerede oplysninger om disse emner, tilbyder vi på vores undersider omfattende analyser: